Former BeiGene Executive Joins Dizal Pharmaceutical as Chief Commercial Officer Amid Hong Kong IPO Filing

Wu Qingyi has confirmed joining Dizal.

Recently, it has been reported that Ms. Wu Qingyi, former Senior Vice President and Chief Commercial Officer for Greater China at BeOne Medicines, has confirmed her joining Dizal to serve as Chief Commercial Officer.

Wu Qingyi joined BeOne Medicines in June 2019 and will leave in September this year.

Prior to joining BeOne Medicines, Wu Qingyi served as Vice President of Sanofi China's Specialty Care Business Unit, where she successfully launched the multiple sclerosis product Aubagio and set a record for the exceptional launch of new products at Sanofi.

From November 2011 to July 2015, Qingyi Wu served as Head of the Diabetes Business Unit at AstraZeneca China, and previously held key positions in sales and marketing within the Oncology Business Unit. Prior to that, she also worked at Genzyme, Pfizer, Eli Lilly, and Bayer.

Wu Qingyi's appointment as Chief Commercial Officer at Dizal may play a pivotal role in advancing the company's commercialization process.

About Dizal

Dizal is an innovation-driven biopharmaceutical company established in October 2017 with capital contributions from AZAB, Advanced Manufacturing, ZYTZ, and Wuxi Lingchuang.

On September 9, 2021, the Shanghai Stock Exchange issued an announcement on the results of the 66th review meeting of the STAR Market Listing Committee in 2021, approving the initial public offering (IPO) of Dizal. The company's current review status is "submitted for registration." For this listing, the company plans to raise approximately RMB 1.783 billion, of which RMB 1.483 billion will be allocated to new drug research and development projects.

Established less than four years ago, Dizal has yet to commercialize any products and has incurred cumulative losses of approximately RMB 1.5 billion over its three and a half years of operation. For the fiscal years 2018, 2019, and 2020, the Company's net losses attributable to shareholders of the parent company were RMB 170 million, RMB 450 million, and RMB 590 million, respectively, with R&D expenses amounting to RMB 210 million, RMB 420 million, and RMB 440 million, respectively.

According to the Reply Report to the Implementation Letter of Opinions from the Listing Review Center regarding its initial public offering application documents, currently, the Company's R&D pipeline includes four innovative drugs in clinical stages for multiple indications, as well as multiple candidate innovative drugs in the preclinical research stage. Among them, DZD9008, DZD1516, DZD2269, and DZD8586 are all independently developed by the Company; the compound patents for DZD4205, DZD2954, and DZD0095 were acquired by the Company from AstraZeneca.

Additionally, according to the prospectus, among the directors, supervisors, senior management, and core technical personnel of Dizal, multiple individuals have prior work experience at AstraZeneca, and Wu Qingyi also has many years of employment history at AstraZeneca.

Managing Editor: Bajiao

Disclaimer: This article is republished by Yaozhi Network. The copyright belongs to the original author(s). It is reproduced for the purpose of information dissemination and does not represent the views of this platform. Should there be any issues regarding the content, copyright, or other matters, please contact us by leaving a message on this website, and we will promptly remove the content!